

## Redemplo (plozasiran)

### POLICY

#### I. INDICATION

Redemplo is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

#### II. INITIAL CRITERIA FOR APPROVAL

##### **Familial Chylomicronemia Syndrome (FCS)**

An authorization of 12 months may be granted when the requested drug is being prescribed to lower triglyceride levels when all of the following criteria are met:

1. Member is 18 years of age or older
2. The medication is prescribed by or in consultation with a lipidologist or specialist familiar with the treatment of FCS.
3. Documentation that member has a confirmed diagnosis of FCS by one of the following:
  - a. Genetic testing (i.e., biallelic pathogenic variants in FCS-causing genes [e.g., lipoprotein lipase (LPL), glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1), apolipoprotein A-V (APOA5), apolipoprotein C-II (APOC2), or lipase maturation factor 1 (LMF1), glycerol-3-phosphate dehydrogenase 1 (GPD1)])
  - b. National Acute Familial Chylomicronemia Syndrome (NAFCS) Score  $\geq 60$
  - c. Member has recurrent acute pancreatitis
4. Documentation that member has a fasting triglyceride level  $\geq 880$  mg/dL (10 mmol/L)
5. Documentation that member is refractory to standard triglyceride-lowering therapies (e.g., statins, fibrates, or other lipid-lowering medications)
6. Secondary factors have been excluded (e.g., high alcohol intake, uncontrolled diabetes, medications, and medical conditions known to increase TG)
7. Member is adherent to and will continue with a low-fat diet (e.g.,  $\leq 20$  to 30 grams of total fat per day, 10% to 15% of calories per day of fat)
8. Member is not using medication in combination with Tryngolza (olezarsen)
9. Prescriber attests to monitoring member's fasting glucose/HbA1c before and during treatment
10. Coverage will not be provided for a diagnosis of multifactorial chylomicronemia (MCS)

#### III. CONTINUATION OF THERAPY

##### **Familial Chylomicronemia Syndrome (FCS)**

An authorization of 12 months may be granted for continued treatment in members requesting reauthorization for FCS when all of the following criteria are met:

1. Documentation supporting a positive clinical response with the requested medication (e.g., reduction in fasting triglyceride level from baseline, reduction in episodes of acute pancreatitis)
2. The member continues to be adherent to a low-fat diet (e.g.,  $\leq 20$  to 30 grams of total fat per day, 10% to 15% of calories per day of fat)

3. The member continues to be managed by or in consultation with a lipidologist or specialist familiar with the treatment of FCS.
4. Member is not using medication in combination with Tryngolza (olezarsen)

#### IV. DOSAGE AND ADMINISTRATION

The recommended dosage of Redempro is 25 mg administered subcutaneously once every 3 months.

#### V. QUANTITY LIMIT

Redempro 25 mg/0.5 mL single-dose prefilled syringe: 1 prefilled syringe (0.5 mL) per 90 days

#### VI. REFERENCES

1. Redempro [package insert]. Pasadena, CA: Arrowhead Pharmaceuticals, Inc.; November 2025.
2. Ballantyne CM, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. *N Engl J Med*. 2024;391(10):899-912. doi:10.1056/NEJMoa2404143
3. Davidson M, et al. The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study. *J Clin Lipidol*. 2018;12(4):898–907. doi:10.1016/j.jacl.2018.04.009
4. Ellerton C, et al. Current dietary practice in the management of adults with familial chylomicronaemia syndrome: a UK expert panel opinion piece. Complete Nutrition website. September 2021. Accessed December 1, 2025. <https://www.heartuk.org.uk/downloads/health-professionals/nutrition-academy/ellerton-et-al-2021.-fcs-dietary-management-uk-expert-panel-opinion.pdf>
5. Gaudet D, et al. Targeting APOC3 in the familial chylomicronemia syndrome. *N Engl J Med*. 2014;371(23):2200-2206. doi:10.1056/NEJMoa1400284
6. Grundy SM, et al. 2018  
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/ PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625
7. Handelsman Y, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary. *Endocr Pract*. 2020;26(10):1196–1224. doi:10.4158/CS-2020-0490
8. Hegele RA, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. *J Clin Lipidol*. 2025; 19(1):83-94. doi:10.1016/j.jacl.2024.09.008
9. Ionis Pharmaceuticals. Tryngolza FDA approval. December 19, 2024. Accessed December 1, 2025. <https://ir.ionis.com/static-files/ec728290-6f75-4391-93b0-f57752094603>
10. Javed F, et al. Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association. *J Clin Lipidol*. 2025;19(3):382-403. doi:10.1016/j.jacl.2025.03.013
11. Németh Á, et al. Identifying patients with familial chylomicronemia syndrome using FCS score-based data mining methods. *J Clin Med*. 2022;11(15):4311. doi:10.3390/jcm11154311

12. Rabacchi C, et al. Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia. *Atherosclerosis*. 2015;241(1):79–86. doi:10.1016/j.atherosclerosis.2015.04.815
13. Watts GF, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. *N Engl J Med*. 2025;392(2):127–137. doi:10.1056/NEJMoa2409368
14. Williams L, et al. Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span. *J Clin Lipidol*. 2018;12(4):908–919. doi:10.1016/j.jacl.2018.04.010.